Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LYT-200 by Puretech Health for Refractory Acute Myeloid Leukemia: Likelihood of Approval
LYT-200 is under clinical development by Puretech Health and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
LYT-200 by Puretech Health for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
LYT-200 is under clinical development by Puretech Health and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
LYT-200 by Puretech Health for Myelodysplastic Syndrome: Likelihood of Approval
LYT-200 is under clinical development by Puretech Health and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
LYT-200 by Puretech Health for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
LYT-200 is under clinical development by Puretech Health and currently in Phase II for Recurrent Head And Neck Squamous Cell...